相关实验视频
Updated: Jan 10, 2026

10:52
Closure of a Patent Foramen Ovale PFO: An Intervention Sequence
Published on: December 23, 2022
5.3K
作为耐火性心力衰竭的二线疗法,心房隔膜缺陷的关闭:一个成功的病例报告在一个6岁的孩子与糖突变酶1缺乏 (PGM1-CDG) 的情况
Sofiane Mimoun1, Alban-Elouen Baruteau1,2,3,4, Bruno Lefort5,6
1Nantes Université, CHU Nantes, Department of Pediatric Cardiology and Pediatric Cardiac Surgery, FHU PRECICARE, 7 quai Moncousu, 44093 Nantes cedex 01, Nantes F-44000, France.
European heart journal. Case reports
|November 27, 2025
概括
耳前隔膜缺陷 (ASD) 关闭可以为左心室符合性受损的患者提供拯救生命的选择. 使用窗体装置进行皮肤封闭,成功治疗了由于ASD和心肌炎引起的心力衰竭的儿童.
科学领域:
- 心脏病学 心脏病学
- 儿科 儿科 儿科
- 遗传性心脏病是一种先天性心脏病.
背景情况:
- 前庭隔膜缺陷 (ASD) 是一种常见的先天性心脏缺陷.
- 自闭症在儿童时期通常保持无症状,但当左心室 (LV) 顺应受损时,可能导致心力衰竭.
研究的目的:
- 报告一个成功通过皮肤关闭ASD的病例,该病例发生在患有CDG-PGM1和心力衰竭的儿童身上.
- 为了突出ASD关闭作为治疗选择在选定的患者受损LV合规性.
主要方法:
- 一个患有CDG-PGM1和大型ASD的6岁男孩出现了急性耐火性心力衰竭.
- 他接受了气球遮测试,随后使用手工制造的窗户设备通过皮肤关闭ASD.
主要成果:
- 通过皮肤进行的ASD关闭是成功的,导致从内的快速断奶和完全的临床恢复.
- 在6个月的随访后,LV功能正常化,患者仍然无症状.
结论:
- 在被选中的患者中,ASD关闭可以成为拯救生命的治疗选择,这些患者的 LV 符合性受损.
- 血液动力学评估与气球封闭测试对于评估封闭可行性和设备选择至关重要.
相关概念视频
Cardiomyopathy II: Dilated Cardiomyopathy
447
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
447
Cardiomyopathy III: Hypertrophic Cardiomyopathy
374
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
374
Cardiomyopathy V: Interprofessional Care
314
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
314
Mitral Stenosis III: Medical Management
223
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
223
Cardiomyopathy IV: Restrictive Cardiomyopathy
431
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
431
Mitral Regurgitation III: Medical Management
257
Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
257

